Genetics tests could help provide cystic fibrosis (CF) patients with targeted treatment in future, pilot study authors suggest. Results from a French clinical trial published today in BMC Medicine show how a small percentage of CF sufferers with a rare genetic stop mutation responded positively to
read more »
Source:http://www.medicalnewstoday.com DiscussBury
The first national audit of the care of inflammatory bowel disease (IBD) in the UK has shown marked variation in the resources and quality of care. [click link for full article]
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Ocera Therapeutics Inc. announced today that a Phase 2 exploratory study for AST-120 in patients with active pouchitis was initiated at Cleveland Clinic and that it has also met the 50 percent enrollment target in its pivotal Phase 3 trial of AST-120 in fistulizing Crohn's disease. The Phase 2 exp
read more »
Source:http://www.medicalnewstoday.com DiscussBury
UCB has decided to initiate an additional short-term clinical study of CIMZIATM (certolizumab pegol) to confirm the induction of clinical response in moderate to severe active Crohn's disease. UCB will work closely with the Food and Drug Administration (FDA) to finalise the design of the clinical st...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
A UK scientist is experimenting with a new gene therapy using HIV that could eventually correct faulty genes in cystic fibrosis babies before they are born.A genetic scientist based at University College, London, Suzanne Buckley, has successfully used HIV as a genetical material carrier or "vector" ...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Inflammatory bowel diseases, such as Crohn's disease and Ulcerative Colitis, severely impair the lives of more than four million people worldwide. The development of effective therapies against these diseases requires an understanding of their underlying molecular mechanisms. [click link for full ar...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
AOP Orphan Pharmaceuticals AG ("AOP Orphan") and Lantibio, Inc. ("Lantibio") today announced positive final results from their placebo controlled, double-blinded Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis ("CF"). Moli1901 is being developed by AOP Orphan ...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Abbott announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an ina...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.